BR112021015238A2 - Novos anticorpos de ligação a cd40 - Google Patents

Novos anticorpos de ligação a cd40

Info

Publication number
BR112021015238A2
BR112021015238A2 BR112021015238A BR112021015238A BR112021015238A2 BR 112021015238 A2 BR112021015238 A2 BR 112021015238A2 BR 112021015238 A BR112021015238 A BR 112021015238A BR 112021015238 A BR112021015238 A BR 112021015238A BR 112021015238 A2 BR112021015238 A2 BR 112021015238A2
Authority
BR
Brazil
Prior art keywords
binding
antibodies
new
binding antibodies
human
Prior art date
Application number
BR112021015238A
Other languages
English (en)
Other versions
BR112021015238A8 (pt
Inventor
Philip Kater Aron
Lodewijk Scheffer George
De Weerdt Iris
Jelle Van Der Vliet Johannes
Paul Parren
Denise De Gruijl Tanja
Original Assignee
Lava Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2022494A external-priority patent/NL2022494B1/en
Application filed by Lava Therapeutics B V filed Critical Lava Therapeutics B V
Publication of BR112021015238A2 publication Critical patent/BR112021015238A2/pt
Publication of BR112021015238A8 publication Critical patent/BR112021015238A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

novos anticorpos de ligação a cd40. a presente invenção se refere a novos anticorpos capazes de se ligar a cd40 humano e a novos anticorpos multiespecíficos capazes de se ligar a cd40 humano e de se ligar a um receptor de células t v¿9v¿2 humano. a invenção também se refere a composições farmacêuticas que compreendem os anticorpos da invenção e aos usos dos anticorpos da invenção para tratamento médico.
BR112021015238A 2019-02-01 2020-01-30 Novos anticorpos de ligação a cd40 BR112021015238A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2022494A NL2022494B1 (en) 2019-02-01 2019-02-01 Novel CD40-binding antibodies
NL2024087 2019-10-23
PCT/NL2020/050051 WO2020159368A1 (en) 2019-02-01 2020-01-30 Novel cd40-binding antibodies

Publications (2)

Publication Number Publication Date
BR112021015238A2 true BR112021015238A2 (pt) 2022-02-15
BR112021015238A8 BR112021015238A8 (pt) 2022-08-16

Family

ID=71840475

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015238A BR112021015238A8 (pt) 2019-02-01 2020-01-30 Novos anticorpos de ligação a cd40

Country Status (11)

Country Link
US (1) US20220135694A1 (pt)
EP (1) EP3917960A1 (pt)
JP (1) JP2022519082A (pt)
KR (1) KR20210141466A (pt)
CN (1) CN113993893A (pt)
AU (1) AU2020216250A1 (pt)
BR (1) BR112021015238A8 (pt)
CA (1) CA3128148A1 (pt)
MX (1) MX2021009285A (pt)
SG (1) SG11202108141VA (pt)
WO (1) WO2020159368A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537534A (ja) * 2020-08-14 2023-09-01 ガンマデルタ セラピューティクス リミテッド 多特異性抗ｔｃｒデルタ可変１抗体
EP4259660A1 (en) * 2020-12-10 2023-10-18 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
US20230028110A1 (en) * 2021-02-17 2023-01-26 Adaptate Biotherapeutics Ltd. Anti-tcr delta variable 1 antibodies
EP4355781A1 (en) 2021-06-18 2024-04-24 Autolus Limited Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases
KR20240049318A (ko) * 2021-08-24 2024-04-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Fap/cd40 결합 분자 및 이의 의학적 용도
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
TW202334233A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 結合γδ T細胞之多肽及其用途
CA3208653A1 (en) * 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028480A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
BRPI0619056A2 (pt) 2005-11-28 2011-09-20 Genmab As anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
US20120134993A1 (en) 2009-03-27 2012-05-31 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CA2892193C (en) 2012-11-21 2018-06-19 Pharmabcine Inc. Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same
WO2015156673A1 (en) 2014-04-10 2015-10-15 Stichting Vu-Vumc IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Also Published As

Publication number Publication date
JP2022519082A (ja) 2022-03-18
CN113993893A (zh) 2022-01-28
KR20210141466A (ko) 2021-11-23
CA3128148A1 (en) 2020-08-06
MX2021009285A (es) 2021-11-12
EP3917960A1 (en) 2021-12-08
WO2020159368A1 (en) 2020-08-06
US20220135694A1 (en) 2022-05-05
AU2020216250A1 (en) 2021-08-26
SG11202108141VA (en) 2021-08-30
BR112021015238A8 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
BR112021015238A8 (pt) Novos anticorpos de ligação a cd40
BR112018010018A2 (pt) moduladores de ror-gama
BR112018015603A2 (pt) ?conjugado de enzimas terapêuticas, seu método de preparação, composição farmacêutica, composição para aumentar a transcitose e seu método, composição para aumentar a distribuição de tecido de uma enzima e seu método?
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
DOP2016000156A (es) Composiciones farmacã¿uticas que comprenden azd9291.
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BR112019024747A2 (pt) formulações de dose fixa
BR112022007612A2 (pt) Inibidores de raf quinases
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017022757A2 (pt) derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap)
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
CL2020002957A1 (es) Biarilamidas con grupos de azúcar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteína de choque de calor

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: LAVA THERAPEUTICS N.V. (NL)